Skip to main content

New Drug Approvals 2013 - Pt. III - Pomalidomide (PomalystTM)

ATC Code: L04A (partial)
Wikipedia: Pomalidomide

On February 8th, the FDA approved Pomalidomide (Tradename: Pomalyst; Research Code: CC-4047, IMiD 3), a thalidomide analogue, indicated for the treatment of multiple myeloma in patients who failed to respond to previous therapies (e.g. lenalidomide and bortezomib).

Multiple myeloma is a form of blood cancer that primarily affects older adults, and arises from the accumulation of abnormal plasma cells in the bone marrow. These abnormal plasma cells produce large amounts of unneeded antibodies, which are then deposited in various organs, causing renal failure, polyneuropathy and other myeloma-associated symptoms.

Pomalidomide, an analogue of thalidomide, is an immunomodulatory agent with antineoplastic activity. Like other thalidomide analogs, the exact mechanism of action is yet not fully understood, however in vitro assays demonstrated that pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells, including lenalidomide-resistant multiple myeloma cell lines. It has also been shown that pomalidomide enhanced T cell and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF-α and IL-6). For more information take a look at this review.

Pomalidomide, like other thalidomide derivatives, belongs to the -domide USAN/INN stem. Members of this class are thalidomide, lenalidomide (both approved drugs and licensed by Celgene Corporation), and Mitindomide and Endomide. Pomalidomide is a result of a quest for safer analogs of thalidomide, and has a higher potency than any of its predecessors.

Pomalidomide (IUPAC Name: 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; Canonical smiles: Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12 ; ChEMBL: CHEMBL43452; PubChem: 134780; ChemSpider: 118785; Standard InChI Key: UVSMNLNDYGZFPF-UHFFFAOYSA-N) is a derivative of thalidomide, with a molecular weight of 273.2 Da, 5 hydrogen bond acceptors, 2 hydrogen bond donors, and has an ALogP of -0.65. The compound is therefore fully compliant with the rule of five.

Pomalidomide is available in the capsular form, and the recommended daily dose is 4 mg on days 1-21 of repeated 28-day cycles until disease progression. Following administration of single oral doses in patients with multiple mieloma, the systematic exposure was characterized by an AUC(Τ) of 400 mL and maximum plasma concentration (Cmax) of 75 ng/mL. At steady state, the mean apparent volume of distribution (Vd/F) was 62-138 L. Pomalidomide is weakly bound to human plasma proteins (12-44%).

Pomalidomide is primarily metabolized in the liver by CYP1A2 and CYP3A4, with additional minor contributions from CYP2C19 and CYP2D6. Pomalidomide is also a substrate for P-glycoprotein (P-gp). The elimination median plasma half-life (t1/2) for pomalidomide is approximately 9.5 hours in healthy subjects and 7.5 in patients with multiple mieloma. Pomalidomide has a mean total body clearance (CL/ F) of 7-10 L/hr.

Pomalidomide has been issued with a black box warning due to its teratogenic profile, i.e., it can cause severe life-threatening birth defects, and also due to its higher risk for venous thromboembolism in patients exposed to the drug. Because of Pomalyst’s embryo-fetal risk, it is available only through the Pomalyst Risk Evaluation and Mitigation Strategy (REMS) Program.

The license holder for PomalystTM is Celgene Corporation, and the full prescribing information can be found here.


Popular posts from this blog

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

ChEMBL 29 Released

  We are pleased to announce the release of ChEMBL 29. This version of the database, prepared on 01/07/2021 contains: 2,703,543 compound records 2,105,464 compounds (of which 2,084,724 have mol files) 18,635,916 activities 1,383,553 assays 14,554 targets 81,544 documents Data can be downloaded from the ChEMBL FTP site: .  Please see ChEMBL_29 release notes for full details of all changes in this release: New Deposited Datasets EUbOPEN Chemogenomic Library (src_id = 55, ChEMBL Document IDs CHEMBL4649982-CHEMBL4649998): The EUbOPEN consortium is an Innovative Medicines Initiative (IMI) funded project to enable and unlock biology in the open. The aims of the project are to assemble an open access chemogenomic library comprising about 5,000 well annotated compounds covering roughly 1,000 different proteins, to synthesiz

Identifying relevant compounds in patents

  As you may know, patents can be inherently noisy documents which can make it challenging to extract drug discovery information from them, such as the key targets or compounds being claimed. There are many reasons for this, ranging from deliberate obfuscation through to the long and detailed nature of the documents. For example, a typical small molecule patent may contain extensive background information relating to the target biology and disease area, chemical synthesis information, biological assay protocols and pharmacological measurements (which may refer to endogenous substances, existing therapies, reaction intermediates, reagents and reference compounds), in addition to description of the claimed compounds themselves.  The SureChEMBL system extracts this chemical information from patent documents through recognition of chemical names, conversion of images and extraction of attached files, and allows patents to be searched for chemical structures of interest. However, the curren

Julia meets RDKit

Julia is a young programming language that is getting some traction in the scientific community. It is a dynamically typed, memory safe and high performance JIT compiled language that was designed to replace languages such as Matlab, R and Python. We've been keeping an an eye on it for a while but we were missing something... yes, RDKit! Fortunately, Greg very recently added the MinimalLib CFFI interface to the RDKit repertoire. This is nothing else than a C API that makes it very easy to call RDKit from almost any programming language. More information about the MinimalLib is available directly from the source . The existence of this MinimalLib CFFI interface meant that we no longer had an excuse to not give it a go! First, we added a BinaryBuilder recipe for building RDKit's MinimalLib into Julia's Yggdrasil repository (thanks Mosè for reviewing!). The recipe builds and automatically uploads the library to Julia's general package registry. The build currently targe

New Drug Warnings Browser

As mentioned in the announcement post of  ChEMBL 29 , a new Drug Warnings Browser has been created. This is an updated version of the entity browsers in ChEMBL ( Compounds , Targets , Activities , etc). It contains new features that will be tried out with the Drug Warnings and will be applied to the other entities gradually. The new features of the Drug Warnings Browser are described below. More visible buttons to link to other entities This functionality is already available in the old entity browsers, but the button to use it is not easily recognised. In the new version, the buttons are more visible. By using those buttons, users can see the related activities, compounds, drugs, mechanisms of action and drug indications to the drug warnings selected. The page will take users to the corresponding entity browser with the items related to the ones selected, or to all the items in the dataset if the user didn’t select any. Additionally, the process of creating the join query is no